New optimal therapies for seasonal allergic conjunctivitis: Addressing the entire inflammatory response of allergen exposure

Seasonal allergic conjunctivitis can be safely managed with effective topical agents. Antihistamines (such as Livostin) have a rapid onset, but a short duration of action. Mast cell stabilizers (such as Opticrom) have a longer duration of action, but can take up to four weeks to demonstrate efficacy. Newer dual-acting Patanol acts primarily as an antihistamine with mast cell stabilizer properties. Alocril provides the only dual mechanism of action that has the unique combination of properties: an anti-inflammatory and mast cell stabilizer. This offers significant advantages for patients suffering from allergic conjunctivitis. Alocril is a more potent second- generation mast cell stabilizer that also provides broader spectrum coverage with its anti-inflammatory properties.